Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study

Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study

ABSTRACT In March 2024, ponatinib received accelerated FDA approval for the treatment of newly diagnosed Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) in combination with chemotherapy based on the Phase 3 PhALLCON study (NCT03589326), which demonstrated a higher rate of mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael J. Hanley, Thomas R. Larson, Paul M. Diderichsen, Anna Largajolli, Katrina Hui, Jaydeep Srimani, Bingxia Wang, Alexander Vorog, Neeraj Gupta
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Clinical and Translational Science
Subjects:
dose–response
oncology
pharmacokinetics
pharmacometrics
population PK‐PD
Online Access:https://doi.org/10.1111/cts.70175
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70175

Similar Items